Esperion Therapeutics (ESPR) Gains from Sales and Divestitures (2016 - 2020)
Esperion Therapeutics (ESPR) reported Gains from Sales and Divestitures of $53587.0 for Q2 2020, up 427.95% on a YoY basis from $10150.0 in Q3 2019, and up 431.14% quarter-over-quarter from $10089.0 in Q1 2020.
Esperion Therapeutics (ESPR) Gains from Sales and Divestitures (2016 - 2020) Analysis & Trends
Esperion Therapeutics has reported Gains from Sales and Divestitures for 5 years, with the latest figure at $53587.0 in Q2 2020.
- For the quarter ending Q2 2020, Gains from Sales and Divestitures rose 427.95% year-over-year to $53587.0; the trailing twelve-month figure through Jun 2020 stood at $53587.0 (up 427.95% YoY), and the FY2019 full-year result was $17710.0, up 415.27% from the prior year.
- Gains from Sales and Divestitures for Q2 2020 stood at $53587.0, up from $10089.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $53587.0 in Q2 2020, with the low at $1562.0 in Q1 2017.
- Historically, Gains from Sales and Divestitures has averaged $9047.9 across 5 years, with a median of $4686.0 in 2017.
- Annual changes were most pronounced in 2018 — Gains from Sales and Divestitures plunged 44.99% — and 2020, when it jumped 427.95%.
- Esperion Therapeutics' Gains from Sales and Divestitures stood at $8749.0 in 2016, then declined by 28.59% to $6248.0 in 2017, then tumbled by 44.99% to $3437.0 in 2018, then surged by 415.27% to $17710.0 in 2019, then surged by 202.58% to $53587.0 in 2020.
- The last three Gains from Sales and Divestitures figures came in at $53587.0 (Q2 2020), $10089.0 (Q1 2020), and $17710.0 (Q4 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Esperion Therapeutics | 49.69 Mn | -118.16 Mn | 45.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 53,587.00 |
| Jun 30, 2020 | 53,587.00 |
| Mar 31, 2020 | 10,089.00 |
| Mar 31, 2020 | 10,089.00 |
| Dec 31, 2019 | 17,710.00 |
| Dec 31, 2019 | 17,710.00 |
| Sep 30, 2019 | 13,850.00 |
| Sep 30, 2019 | 13,850.00 |
| Jun 30, 2019 | 10,150.00 |
| Jun 30, 2019 | 10,150.00 |
| Mar 31, 2019 | 3,125.00 |
| Mar 31, 2019 | 3,125.00 |
| Dec 31, 2018 | 3,437.00 |
| Dec 31, 2018 | 3,437.00 |
| Sep 30, 2018 | 2,812.00 |
| Sep 30, 2018 | 2,812.00 |
| Jun 30, 2018 | 2,187.00 |
| Jun 30, 2018 | 2,187.00 |
| Mar 31, 2018 | 1,562.00 |
| Mar 31, 2018 | 1,562.00 |